Kidney Cancer

Targeted Assessments May Be Needed for Some Patients With Localized Renal Cell Carcinoma

By

John Schieszer

Publish Date February 19, 2020

Assessments and interventions for younger and female patients with RCC may need to be targeted, as these patients may have a greater fear of disease recurrence.

Nivolumab Outperforms Everolimus in Advanced RCC, Study Confirms

By

Natasha Persaud

Publish Date February 19, 2020

In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.

Immune Checkpoint Inhibitors for mRCC Safe, Effective in a Real World Setting

By

Jody A. Charnow, Editor

Publish Date February 19, 2020

In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.

Metastasectomy Found to Prolong Survival in Selected mRCC Cases

By

Natasha Persaud

Publish Date February 18, 2020

In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.

Preoperative Bone Metastases Not Prognostic in mRCC

By

Natasha Persaud

Publish Date February 18, 2020

Bone metastases less predictive in the setting of cytoreductive nephrectomy.